Ideas

Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Lansoprazole, Epicatechin and Matrine (LPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/January/2018, 12.41 am
Natural product-based therapy for Diabetic retinopathy: A pharmaceutical mixture encompassing Lansoprazole, Epicatechin and Matrine (LPEM) inhibits Soluble epoxide hydrolase (sEH) expression, decreases toxic 19,20-dihydroxydocosapentaenoic acid levels, inhibits pericyte loss, vascular permeability, and inflammation of the eye and progression of diabetic retinopathy, via down regulation of its target gene, 25/January/2018, 12.41 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Institute for Vascular Signalling, Centre for Molecular Medicine, Goethe University, Frankfurt am Main, Germany; and German Centre for Cardiovascular Research (DZHK) partner…

read more

MMolecular therapy for Diabetic nephropathy (DN): Epigallocatechin (EGCG), isolated from Green tea, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 25/January/2018, 12.33 am
MMolecular therapy for Diabetic nephropathy (DN): Epigallocatechin (EGCG), isolated from Green tea, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 25/January/2018, 12.33 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more

Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing Lopidogrel and Aspirin (CPAP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 25/January/2018,  12.24 am
Molecular therapy for Cardiomyopathy: A pharmacological mixture encompassing Lopidogrel and Aspirin (CPAP) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 25/January/2018,  12.24 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Lansoprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 12.11 am
Molecular therapy for body weight control, energy homeostasis and TIIDM: A pharmaceutical mixture encompassing Lansoprazole and Pyridoxamine  inhibits DNA methyltransferase 3a (Dnmt3a) expression, increases FGF21 expression, augments insulin sensitivity, increases glucose tolerance, and protects from diet-induced obesity and TIIDM, via up regulation of its target gene, 25/January/2017, 12.11 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from Nutritional Sciences and Toxicology Department, University of California, Berkeley, Berkeley, United States shows that “Dnmt3a is an epigenetic mediator of adipose insulin resistance.”…

read more

Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor suppressors CADM1 and RECK1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/January/2018, 12.03 am
Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor suppressors CADM1 and RECK1, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 25/January/2018, 12.03 am 960 720 Dr Boomi's Genom-2-Discovery Center

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more than half of them…

read more

Molecular therapy for Diabetic nephropathy (DN): Valsartan(Trade name: Diovan), an angiotensin converting enzyme inhibitor used in the treatment of hypertension, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 23/January/2018, 11.59 pm
Molecular therapy for Diabetic nephropathy (DN): Valsartan(Trade name: Diovan), an angiotensin converting enzyme inhibitor used in the treatment of hypertension, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 23/January/2018, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the progression of diabetic glomerular…

read more
Start Typing